0001213900-23-049632.txt : 20230616 0001213900-23-049632.hdr.sgml : 20230616 20230616160134 ACCESSION NUMBER: 0001213900-23-049632 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230616 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230616 DATE AS OF CHANGE: 20230616 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ENZO BIOCHEM INC CENTRAL INDEX KEY: 0000316253 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 132866202 STATE OF INCORPORATION: NY FISCAL YEAR END: 0731 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-09974 FILM NUMBER: 231020855 BUSINESS ADDRESS: STREET 1: 60 EXECUTIVE BLVD CITY: FARMINGDALE STATE: NY ZIP: 11735 BUSINESS PHONE: 5167555500 MAIL ADDRESS: STREET 1: ENZO BIOCHEM INC STREET 2: 60 EXECUTIVE BLVD CITY: FARMINGDALE STATE: NY ZIP: 11735 8-K 1 ea180489-8k_enzobio.htm CURRENT REPORT
0000316253 false 0000316253 2023-06-16 2023-06-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): June 16, 2023

 

Enzo Biochem, Inc.

(Exact Name of Registrant as Specified in Its Charter)

 

New York

(State or Other Jurisdiction of Incorporation)

 

001-09974   13-2866202
(Commission File Number)   (IRS Employer
Identification No.)
     
81 Executive Blvd. Suite 3    
Farmingdale, New York   11735
(Address of Principal Executive Offices)   (Zip Code)

 

(212) 583-0100

(Registrant’s Telephone Number, Including Area Code)

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class   Trading Symbol   Name of Each Exchange on Which Registered
Common Stock, $0.01 par value   ENZ   The New York Stock Exchange

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-1 of this chapter). 

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 8.01 - Other Items

 

This Current Report on Form 8-K provides Enzo Biochem, Inc.’s (the “Company”) unaudited pro forma condensed consolidated financial information as of and for the nine months ended April 30, 2023 and for the years ended July 31, 2022 and July 31, 2021 and the notes thereto, based upon financial statements prepared in accordance with accounting principles generally accepted in the United States. Such information is filed as Exhibit 99.1 to this Current Report on Form 8-K, which is incorporated into this Item 8.01 by reference.

 

Forward-Looking Statements

 

This Current Report on Form 8-K contains “forward-looking statements” about the Company’s future expectations, plans, outlook, projections and prospects. Such forward-looking statements can be identified by the use of words such as “should,” “may,” “would,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” “proposes” and similar expressions or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Although the Company believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, these statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Forward-looking statements in this communication include estimates and assumptions, particularly in regard to unaudited pro forma financial information included in Exhibit 99.1 of this Current Report on Form 8-K. Accordingly, readers are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended July 31, 2022. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In addition, readers are cautioned that past performance may not be indicative of future results. In light of the significant uncertainties in these forward-looking statements, readers should not rely on these statements in making an investment decision or regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. Forward-looking statements speak only as of the date of the document in which they are contained, and the Company does not undertake any duty to update any forward-looking statements except as may be required by law. Therefore, readers should not rely on these forward-looking statements as representing the Company’s views as of any date subsequent to the date of this communication. 

 

Item 9.01 Financial Statements and Exhibits

 

(d) Exhibits.

 

Exhibit No.   Description
99.1   Unaudited Pro Forma Condensed Consolidated Financial Information of the Company.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

1

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ENZO BIOCHEM, INC.
     
Date: June 16, 2023 By: /s/ Hamid Erfanian
    Hamid Erfanian
    Chief Executive Officer

 

 

2

 

 

 EX-99.1 2 ea180489ex99-1_enzobio.htm UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION OF THE COMPANY

Exhibit 99.1

 

UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION

 

(in thousands, except share and per share data)

 

The following unaudited pro forma condensed consolidated financial information is based upon the historical consolidated statements of Enzo Biochem, Inc., a New York corporation (the “Company”), adjusted to give effect to the sale (the “Asset Sale”) of substantially all the operating assets and assign certain liabilities of the Company’s clinical laboratory business (the “Business”) in accordance with the Asset Purchase Agreement dated March 16, 2023 (the “Asset Purchase Agreement”) between the Company, Enzo Clinical Labs, Inc., a New York corporation (the “Seller”), and Laboratory Corporation of America Holdings, a Delaware corporation (the “Buyer”). These unaudited pro forma condensed consolidated financial statements are derived from, and should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended July 31, 2022 filed with the United States Securities and Exchange Commission (the “SEC”) on October 14, 2022 as amended on November 24, 2022, and the Quarterly Report on Form 10-Q for the interim period ended April 30, 2023, filed with the SEC on June 14, 2023.

 

The unaudited pro forma condensed consolidated balance sheet gives effect to the proposed Asset Sale as if it had occurred on April 30, 2023. The estimated cash proceeds and impact of the resulting gain are only included in the April 30, 2023 unaudited pro forma condensed consolidated balance sheet. The unaudited pro forma condensed consolidated statements of operations for the nine months ended April 30, 2023 and the years ended July 31, 2022 and 2021 give effect to the proposed Asset Sale as if it had occurred on August 1, 2020.

 

The pro forma adjustments related to the sale of the Business are based on available information and assumptions that management believes are (1) directly attributable to the Asset Sale; (2) factually supportable; and (3) with respect to the unaudited pro forma condensed consolidated statements of operations, expected to have a continuing impact on consolidated operating results. Certain of the most significant assumptions are set forth under the Notes to Unaudited Pro Forma Condensed Consolidated Financial Information.

 

The unaudited pro forma condensed consolidated financial information is not necessarily indicative of the results of operations or financial position that might have been achieved for the dates or periods indicated, nor is it indicative of the results of operations or financial position that may occur in the future. Furthermore, the pro forma adjustments may differ from those that will be calculated for purposes of reporting discontinued operations in future filings. The Company cautions shareholders that its future results of operations, including uses of cash and financial position, may significantly differ from those described in these unaudited pro forma condensed consolidated financial statements, and accordingly, these unaudited pro forma condensed consolidated financial statements should be read in conjunction with the disclosures regarding the nature of the Company’s business following completion of the transactions contemplated by the Asset Purchase Agreement.

 

 

 

 

UNAUDITED PRO FORMA CONDENSED CONSOLIDATED BALANCE SHEET
As of April 30, 2023
(in thousands, except share and per share data)

 

   Historical   Pro Forma
Adjustments		      Pro Forma 
ASSETS               
Current assets:               
Cash and cash equivalents   2,632    136,648   (a)   139,280 
Accounts receivable, net   9,636    —       9,636 
Inventories, net   15,289    (6,988)  (b)   8,301 
Prepaid expenses and other current assets   4,442    (2,028)  (b)   2,414 
Total current assets   31,999    127,632       159,631 
                   
Property, plant, and equipment, net   17,506    (4,815)  (b)   12,691 
Right-of-use assets, net   13,457    (957)  (b)   12,500 
Goodwill   7,452    (7,452)  (b)   — 
Other, including restricted cash of $1,000   1,647    (272)  (b)   1,375 
Total assets  $72,061   $114,136      $186,197 
                   
LIABILITIES AND STOCKHOLDERS’ EQUITY                  
Current liabilities:                  
Accounts payable – trade  $13,645   $—      $13,645 
Accrued liabilities   17,494    12,704   (c)   30,198 
Current portion of operating lease liabilities   3,706    (291)  (b)   3,415 
Mortgage debt, net   3,821    —       3,821 
Loans payable, net   3,354            3,354 
Other current liabilities and finance leases short term   132    —       132 
Total current liabilities   42,152    12,413       54,565 
                   
Operating lease liabilities, non-current, net   10,734    (678)  (b)   10,056 
Long term debt, net   247    —       247 
Total liabilities  $53,133   $11,735      $64,868 
                   
Stockholders’ equity:                  
Common Stock, $.01 par value; authorized 75,000,000 shares; 49,669,488 shares issued and outstanding   496    —       496 
Additional paid-in capital   342,055    —       342,055 
Accumulated deficit   (325,780)   102,401   (c)   (223,379)
Accumulated other comprehensive income   2,157    —       2,157 
Total stockholders’ equity   18,928    102,401       121,329 
                   
Total liabilities and stockholders’ equity  $72,061   $114,136      $186,197 

 

The accompanying notes are an integral part of these unaudited pro forma condensed consolidated financial statements.

 

2

 

 

UNAUDITED PRO FORMA CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
For the nine months ended April 30, 2023
(in thousands, except share and per share data)

 

   Historical   Pro Forma
Adjustments		      Pro Forma 
Revenues  $50,721   $(28,619)  (d)  $22,102 
                   
Operating costs and expenses:                  
Cost of revenues   44,219    (30,538)  (d)   13,681 
Research and development   3,402    (694)  (d)   2,708 
Selling, general and administrative   35,285    (19,830)  (d)   15,455 
Legal and related expense, net   6,352    (192)  (d)   6,160 
Total operating costs and expenses   89,258    (51,254)      38,004 
                   
Operating loss   (38,537)   22,635       (15,902)
                   
Other income (expense):                  
Interest, net   95    4   (d)   99 
Other   278    (16)  (d)   262 
Foreign exchange gain   1,022    —       1,022 
Total other income (expense)   1,395    (12)      1,383 
                   
Loss before income taxes   (37,142)   22,623       (14,519)
Income taxes   —    —       — 
Net loss  $(37,142)  $22,623      $(14,519)
                   
Net loss per common share:                  
Basic and diluted  $(0.76)          $(0.30)
                   
Weighted average common shares outstanding:                  
Basic and diluted   48,944            48,944 

 

The accompanying notes are an integral part of these unaudited pro forma condensed consolidated financial statements.

 

3

 

 

UNAUDITED PRO FORMA CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
For the year ended July 31, 2022
(in thousands, except share and per share data)

 

   Historical   Pro Forma
Adjustments		      Pro Forma 
Revenues  $107,071   $(74,428)  (d)  $32,643 
                   
Operating costs and expenses:                  
Cost of revenues   65,104    (45,891)  (d)   19,213 
Research and development   3,767    (1,329)  (d)   2,438 
Selling, general and administrative   48,018    (26,173)  (d)   21,845 
Legal and related expense, net   5,689    (254)  (d)   5,435 
Legal settlements   (500)           (500)
Total operating costs and expenses   122,078    (73,647)      48,431 
                   
Operating loss   (15,007)   (781)      (15,788)
                   
Other income (expense):                  
Interest, net   159    19   (d)   178 
Other   (1,191)   (77)  (d)   (1,268)
Foreign exchange loss   (2,222)   —       (2,222)
Total other expense   (3,254)   (58)      (3,312)
                   
Loss before income taxes   (18,261)   (839)      (19,100)
Income taxes   —    —       — 
Net loss  $(18,261)  $(839)     $(19,100)
                   
Net loss per common share:                  
Basic and diluted  $(0.38)          $(0.39)
                   
Weighted average common shares outstanding:                  
Basic and diluted   48,594            48,594 

 

The accompanying notes are an integral part of these unaudited pro forma condensed consolidated financial statements.

 

4

 

 

UNAUDITED PRO FORMA CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
For the year ended July 31, 2021
(in thousands, except share and per share data)

 

   Historical   Pro Forma
Adjustments		      Pro Forma 
Revenues  $117,731   $(86,984)  (d)  $30,747 
                   
Operating costs and expenses:                  
Cost of revenues   64,154    (48,179)  (d)   15,975 
Research and development   3,252    (615)  (d)   2,637 
Selling, general and administrative   44,905    (26,028)  (d)   18,877 
Legal and related expense, net   4,728    (264)  (d)   4,464 
Total operating costs and expenses   117,039    (75,086)      41,953 
                   
Operating income (loss)   692    (11,898)      (11,206)
                   
Other income (expense):                  
Interest, net   8    17   (d)   25 
Other   6,905    18   (d)   6,923 
Foreign exchange (loss) gain   270    —       270 
Total other income   7,183    35       7,218 
                   
Income (loss) before income taxes   7,875    (11,863)      (3,988)
Income taxes   —    —       — 
Net income (loss)  $7,875   $(11,863)     $(3,988)
                   
Net income (loss) per common share:                  
Basic  $0.16           $(0.08)
Diluted  $0.16           $(0.08)
                   
Weighted average common shares outstanding:                  
Basic   48,191            48,191 
Diluted   48,325            48,191 

 

The accompanying notes are an integral part of these unaudited pro forma condensed consolidated financial statements.

 

5

 

 

NOTES TO UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION

 

(in thousands, except share and per share data)

 

1. Planned Asset Sale

 

On March 16, 2023, Enzo Biochem, Inc., a New York corporation (the “Company”), Enzo Clinical Labs, Inc., a New York corporation (the “Seller”) entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) with Laboratory Corporation of America Holdings, a Delaware corporation (the “Buyer”). Pursuant to the Asset Purchase Agreement, the Seller has agreed to sell substantially all the operating assets and assign certain liabilities of its clinical laboratory business (the “Business”) to the Buyer in exchange for approximately $146.0 million in cash, on and subject to the terms and conditions set forth therein (such transaction, the “Asset Sale”). The purchase price remains subject to adjustment pursuant to the terms of the Asset Purchase Agreement.

 

2. Unaudited Pro Forma Adjustments

 

The preparation of the unaudited pro forma consolidated financial information is based on financial statements prepared in accordance with accounting principles generally accepted in the United States. The pro forma adjustments reflected in the accompanying unaudited pro forma consolidated financial information reflect estimates and assumptions that we believe to be directly attributable to the Asset Sale and factually supportable. Actual results may differ from those estimates.

 

The unaudited pro forma consolidated financial information is provided for illustrative purposes only and does not purport to represent what the actual results of operations would have been had the Asset Sale occurred on the respective dates assumed, nor is it necessarily indicative of our future operating results. The unaudited pro forma consolidated financial information and the accompanying unaudited notes should be read in conjunction with our consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended July 31, 2022 filed with the SEC on October 14, 2022 as amended on November 24, 2022, and the Quarterly Report on Form 10-Q for the interim period ended April 30, 2023, filed with the SEC on June 14, 2023.

 

The pro forma adjustments are based on the Company’s preliminary estimates and assumptions which are subject to change. The following pro forma adjustments, related to the proposed Asset Sale, are included in the unaudited pro forma condensed consolidated balance sheet and/or the unaudited pro forma condensed consolidated statements of operations.

 

6

 

 

(a)Represents cash proceeds under the terms of the Asset Purchase Agreement of $146.0 million (subject to certain adjustments and assuming full release of the $5.0 million placed into an escrow account for the purpose of satisfying claims, if any, made by Buyer pursuant to the indemnification provisions included in the Asset Purchase Agreement), net of transaction-related expenses of $9.4 million. Estimated transaction-related expenses are summarized as follows (amounts in thousands):

 

Banker success fees and expenses  $3,075 
Legal and accounting fees   2,700 
Contingent transaction bonuses   3,577 
   $9,352 

 

(b)Represents transfer of assets to the Buyer and the assumption of liabilities by the Buyer under the terms of the Asset Purchase Agreement.

 

(c)The overall adjustment to accumulated deficit represents the estimated after-tax gain on the sale of the assets of $102.4 million, which is calculated as follows (amounts in thousands):

 

Cash purchase price  $146,000 
Less estimated transaction-related expenses   9,352 
Net proceeds   136,648 
Less net assets sold under the Asset Purchase Agreement   21,543 
Less estimated income taxes   12,704 
After-tax gain on sale of assets  $102,401 

 

The actual after-tax gain will be a different amount. Management expects to utilize substantially all of the Company’s historical tax attributes to offset a substantial portion of its taxable income arising from the Asset Sale. The estimated income taxes resulting from the Asset Sale are reflected as an adjustment to the accrued liabilities in the unaudited pro forma condensed consolidated balance sheet; however, the estimated after-tax gain on the Asset Sale has not been reflected in the unaudited pro forma condensed consolidated statements of operations as it is considered to be nonrecurring in nature.

 

(d)Represents the elimination of Revenue, Cost of Revenue, Research and Development, Selling, General and Administrative, Legal Fee Expense, and Other Income related to the Business for the periods presented. These adjustments have no effect on the Company’s income taxes for all periods presented based on the Company being in a loss position with a full valuation allowance.

 

7

 

 EX-101.SCH 3 enz-20230616.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 enz-20230616_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 enz-20230616_pre.xml XBRL PRESENTATION FILE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover
Jun. 16, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 16, 2023
Entity File Number 001-09974
Entity Registrant Name Enzo Biochem, Inc.
Entity Central Index Key 0000316253
Entity Tax Identification Number 13-2866202
Entity Incorporation, State or Country Code NY
Entity Address, Address Line One 81 Executive Blvd. Suite 3
Entity Address, City or Town Farmingdale
Entity Address, State or Province NY
Entity Address, Postal Zip Code 11735
City Area Code 212
Local Phone Number 583-0100
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.01 par value
Trading Symbol ENZ
Security Exchange Name NYSE
Entity Emerging Growth Company false
XML 7 ea180489-8k_enzobio_htm.xml IDEA: XBRL DOCUMENT 0000316253 2023-06-16 2023-06-16 iso4217:USD shares iso4217:USD shares 0000316253 false 8-K 2023-06-16 Enzo Biochem, Inc. NY 001-09974 13-2866202 81 Executive Blvd. Suite 3 Farmingdale NY 11735 212 583-0100 false false false false Common Stock, $0.01 par value ENZ NYSE false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://enzo.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ea180489-8k_enzobio.htm ea180489ex99-1_enzobio.htm enz-20230616.xsd enz-20230616_lab.xml enz-20230616_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ea180489-8k_enzobio.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "contextCount": 1, "dts": { "inline": { "local": [ "ea180489-8k_enzobio.htm" ] }, "labelLink": { "local": [ "enz-20230616_lab.xml" ] }, "presentationLink": { "local": [ "enz-20230616_pre.xml" ] }, "schema": { "local": [ "enz-20230616.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "ENZ", "nsuri": "http://enzo.com/20230616", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "ea180489-8k_enzobio.htm", "contextRef": "From2023-06-16to2023-06-16", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://enzo.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "ea180489-8k_enzobio.htm", "contextRef": "From2023-06-16to2023-06-16", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://enzo.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0001213900-23-049632-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-23-049632-xbrl.zip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end